Discovery and development of DNA methyltransferase inhibitors using in silico approaches

Drug Discov Today. 2015 May;20(5):569-77. doi: 10.1016/j.drudis.2014.12.007. Epub 2014 Dec 16.

Abstract

Multiple strategies have evolved during the past few years to advance epigenetic compounds targeting DNA methyltransferases (DNMTs). Significant progress has been made in HTS, lead optimization and determination of 3D structures of DNMTs. In light of the emerging concept of epi-informatics, computational approaches are employed to accelerate the development of DNMT inhibitors helping to screen chemical databases, mine the DNMT-relevant chemical space, uncover SAR and design focused libraries. Computational methods also synergize with natural-product-based drug discovery and drug repurposing. Herein, we survey the latest developments of in silico approaches to advance epigenetic drug and probe discovery targeting DNMTs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Binding Sites
  • Computer Simulation*
  • Computer-Aided Design*
  • DNA Methylation / drug effects*
  • DNA Modification Methylases / antagonists & inhibitors*
  • DNA Modification Methylases / chemistry
  • DNA Modification Methylases / metabolism
  • Data Mining
  • Databases, Chemical
  • Databases, Pharmaceutical
  • Drug Discovery / methods*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / therapeutic use*
  • Epigenesis, Genetic / drug effects*
  • Gene Expression Regulation / drug effects
  • Humans
  • Ligands
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Protein Binding
  • Protein Conformation
  • Structure-Activity Relationship

Substances

  • Enzyme Inhibitors
  • Ligands
  • DNA Modification Methylases